These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 10881027

  • 1. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K.
    Prostate; 2000 Jul 01; 44(2):172-80. PubMed ID: 10881027
    [Abstract] [Full Text] [Related]

  • 2. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
    Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL.
    Proc Natl Acad Sci U S A; 2003 Dec 23; 100(26):15836-41. PubMed ID: 14660794
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL.
    Prostate; 2002 Aug 01; 52(3):173-82. PubMed ID: 12111694
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J, Halmos G, Szepeshazi K, Schally AV.
    Cancer; 1993 Dec 01; 72(11):3263-70. PubMed ID: 8242552
    [Abstract] [Full Text] [Related]

  • 9. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
    Kahán Z, Varga JL, Schally AV, Rékási Z, Armatis P, Chatzistamou L, Czömpöly T, Halmos G.
    Breast Cancer Res Treat; 2000 Mar 01; 60(1):71-9. PubMed ID: 10845811
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR, Radulovic S, Groot K, Schally AV.
    Prostate; 1992 Mar 01; 20(4):269-80. PubMed ID: 1376910
    [Abstract] [Full Text] [Related]

  • 12. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
    Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL.
    Int J Cancer; 2004 Nov 20; 112(4):570-6. PubMed ID: 15382037
    [Abstract] [Full Text] [Related]

  • 13. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
    Koppán M, Halmos G, Arencibia JM, Lamharzi N, Schally AV.
    Cancer; 1998 Oct 01; 83(7):1335-43. PubMed ID: 9762934
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
    Letsch M, Schally AV, Busto R, Bajo AM, Varga JL.
    Proc Natl Acad Sci U S A; 2003 Feb 04; 100(3):1250-5. PubMed ID: 12538852
    [Abstract] [Full Text] [Related]

  • 16. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL.
    Prostate; 2008 Dec 01; 68(16):1763-72. PubMed ID: 18729085
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L, Arenas MI, Schally AV, Fernández-Martínez AB, Zarka E, González-Santander M, Carmena MJ, Vacas E, Prieto JC, Bajo AM.
    Int J Cancer; 2013 Feb 15; 132(4):755-65. PubMed ID: 22777643
    [Abstract] [Full Text] [Related]

  • 18. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ.
    Br J Cancer; 1994 Nov 15; 70(5):886-92. PubMed ID: 7947094
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F, Arencibia JM.
    Cancer Lett; 2001 Sep 28; 171(1):37-45. PubMed ID: 11485826
    [Abstract] [Full Text] [Related]

  • 20. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G, Schally AV.
    Proc Natl Acad Sci U S A; 1997 Feb 04; 94(3):956-60. PubMed ID: 9023364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.